- WuXi Biologics and Sinorda Biomedicine collaborate on SND006 for autoimmune diseases.
- Sinorda plans to submit IND applications to NMPA and FDA in 2026.
- WuXi Biologics supports 945 client projects, including 74 in Phase III.
- Sinorda's Linaprazan glureta is approved for commercialization.
Collaboration Overview
WuXi Biologics and Sinorda Biomedicine have announced a strategic partnership to develop and manufacture SND006, a bispecific antibody aimed at treating inflammatory bowel disease and other autoimmune conditions.
Development and Regulatory Plans
Sinorda Biomedicine will utilize WuXi Biologics' expertise to advance SND006's preclinical studies and clinical supply, expediting the Investigational New Drug (IND) application process. Sinorda plans to submit IND applications to both the National Medical Products Administration in China and the U.S. Food and Drug Administration in 2026.
Future Collaboration
The partnership may expand to include multiple projects, from molecule discovery to clinical manufacturing, around Sinorda Biomedicine's potential pipeline.
Company Backgrounds
WuXi Biologics is a global Contract Research, Development, and Manufacturing Organization supporting 945 client projects, including 74 in Phase III. Sinorda Biomedicine focuses on innovative drugs for digestive tract diseases, tumor immunity, and autoimmune diseases, with Linaprazan glureta already approved for commercialization.
